Lisa Wipperman Heine, COO of Mitralign, says the FDA is making quicker work of review times. But the same might not be said for other countries where Medtechs once had a faster time to market. In this interview at the offices of Fox Rothschild in Minneapolis, the Medtech veteran lays out Mitralign’s success with the agency’s Early Feasibility program.
Read more about Mitralign here.
Lisa Wipperman Heine
Lisa Wipperman Heine is currently COO at Mitralign, Inc., an early stage, venture backed medtech company focused on transcatheter heart valve annuloplasty.